Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Basiliximab.

S V Onrust1, L R Wiseman

  • 1Adis International Limited, Auckland, Mairangi Bay, New Zealand. demail@adis.co.nz

Drugs
|April 3, 1999
PubMed
Summary
This summary is machine-generated.

Basiliximab, an interleukin-2 (IL-2) receptor blocker, effectively prevents T lymphocyte activation. This monoclonal antibody significantly reduces acute rejection episodes in renal transplant patients, demonstrating good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trastuzumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Perospirone.

CNS drugs·2001
Same author

Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

Drugs·2000
Same author

Calfactant: a review of its use in neonatal respiratory distress syndrome.

Paediatric drugs·2000
Same author

Docetaxel: an update of its use in advanced breast cancer.

Drugs·2000
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Basiliximab is a chimaeric monoclonal antibody targeting the interleukin-2 (IL-2) receptor.
  • It acts as a competitive antagonist to IL-2, modulating T lymphocyte activation.

Purpose of the Study:

  • To evaluate the efficacy and safety of basiliximab in preventing acute rejection after renal transplantation.
  • To assess the binding kinetics and duration of basiliximab on IL-2 receptors.

Main Methods:

  • Two large, randomized, placebo-controlled trials were conducted.
  • Basiliximab was administered intravenously at a dose of 20 mg, 2 hours before and 4 days after transplantation.
  • IL-2 receptor occupancy and biopsy-confirmed acute rejection episodes were monitored.

Related Experiment Videos

Main Results:

  • Basiliximab achieved approximately 90% IL-2 receptor blockade within 24 hours, sustained for 4-6 weeks.
  • Patients receiving basiliximab showed significantly lower rates of acute rejection (30-33%) compared to placebo (44-46%) at 6 months.
  • The incidence of infections and post-transplant lymphoproliferative disorders was comparable between groups.

Conclusions:

  • Basiliximab is an effective immunosuppressive agent for renal transplantation.
  • It significantly reduces acute rejection episodes with a favorable safety profile.
  • No cytokine release syndrome was observed in patients treated with basiliximab.